Quick orientationEvidence update: 6 October 2026
What is DSIP?
DSIP stands for Delta Sleep-Inducing Peptide, which is an extraordinarily bold name for something whose sleep evidence is actually rather complicated.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Older small human studies reported mixed sleep findings.
What the mechanism suggests
Delta sleep-inducing peptide is a small neuropeptide studied historically in sleep and stress physiology.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Delta sleep-inducing peptide is a small neuropeptide studied historically in sleep and stress physiology.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Chronic insomnia double-blind study — 1992
Double-blind matched-pairs trial · 16 chronic insomniacsThree afternoon IV doses of 25 nmol/kg produced some improvements in sleep efficiency and latency, but the authors judged the effects weak and possibly driven partly by changes in placebo.
The name promises more than the evidence: small old studies produced mixed results.
What it doesn't prove: Tiny study, intravenous research dosing and several outcomes showed no benefit.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Healthy volunteers | 25 nmol/kg IV slow infusion | Single administration | None | 6-person double-blind crossover |
| Chronic insomnia | 25 nmol/kg IV in afternoon before nights 3–5 | 3 consecutive treatment days | Fixed | 16-patient double-blind study |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Common bedtime range | 100–300 mcg SC before bed | Often 4–8 weeks | May be fixed | Community |
| Daily titration example | 100 week 1 →150 week 2 →200 week 3 →250–300 mcg weeks 4–8 | 8 weeks | Weekly step-up | Community protocol |
| 3× weekly pattern | 100 mcg 3×/week →150 mcg 3×/week after response review | Weeks to months | Slow increase | Expert/community compilation |
| Upper community range | 200–500 mcg daily | 4–8 weeks | Gradual increase sometimes reported | Community |
Human trials used IV weight-based dosing, not SC bedtime microgram protocols. The insomnia trial found only weak effects and concluded major therapeutic benefit was unlikely.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Evidence is limited and inconsistent; modern clinical validation is lacking.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
The name promises more than the evidence: small old studies produced mixed results.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.